All In Biotech

Drug Trial Radar · NCT01787383

A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities

Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Feb 2013

Primary completion

Jan 2014

Study completion Jan 2014

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Feb 8, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to evaluate the safety of a simultaneous treatment regimen compared to a sequential treatment regimen when two separate areas with AKs (one located on face/scalp and the other located on trunk/ extremities) are treated with ingenol mebutate gel

Conditions

  • Actinic Keratosis

Interventions

  • Ingenol mebutate gel 0.05 %Drug

    Ingenol mebutate gel 0.05 % (Picato®) on trunk/extremities either applied simultaneously or sequentially

  • Ingenol mebutate gel 0.015 %Drug

    Ingenol mebutate gel 0.015 % (Picato®) on face/scalp either applied simultaneously or sequentially

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite Local Skin Reaction (LSR) Score 3 Days After Treatment of Each Selected Treatment AreaTime frame: 3 days after treatment of each selected treatment area

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinica Dermatologica dell'Università di Modena e Reggio Emilia

    Modena, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.